In the course of the ALS development program, however, dexpramipexole was observed to produce a significant and targeted depletion of eosinophils in the blood of ALS patients 4. Eosinophils are ...

--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of eosinophilic ...

Areteia Therapeutic’s CEO, Jorge Bartolome, shared his company’s novel and first oral drug development to treat eosinophilic ...

Leerink Partners analyst Thomas Smith has reiterated their neutral stance on ALLK stock, giving a Hold rating on January 27.Invest with ...